Skip to content Skip to footer
Subscribe Now
A Complete Account of EMA Approvals in 2023
INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots:  In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology  For…
March 5, 2024

Read more

35th World Congress for Neurorehabilitation New Advances in Neurorehabilitation
EVENTS

35th World Congress for Neurorehabilitation: New Advances in Neurorehabilitation

Conference Series is delighted to welcome you to attend the “35th World Congress for Neurorehabilitation” to be held in Amsterdam, Netherlands, from August 07-08, 2023. The exhilarating scientific program will focus on Clinical Neurology, Cognitive Neuroscience Neurorehabilitation, Neurosurgery, Psychiatry.  The two days program will be filled with insightful presentations, engaging discussions, and networking opportunities. This…
July 7, 2023

Read more

Viewpoints_Jay Pathmanathan
VIEWPOINTS

Jay Pathmanathan, Medical Director at Beacon Biosignals Shares Insights on EEG Neurobiomarkers for the Development of Precision Medicines in Neurology

Shots: Jay spoke about the role of AI-based EEG neurobiomarkers in the development of therapies to treat neurologic diseases Jay also talked about the use of the EEG analytics platform for dose determination clinical research The interview gives an understanding of Beacon Biosignals' vision to accelerate new treatment options for neurological and psychiatric diseases Smriti: Throw…
September 27, 2022

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots: The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD Conference The spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD  The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 2022

Read more